From: Accumulation of copy number alterations and clinical progression across advanced prostate cancer
Clinical trial endpoint | Estimated survival (%) | |||
---|---|---|---|---|
Copy number alteration burden (Quartile) | Q1 | Q2 | Q3 | Q4 |
Failure-free survival | 63 | 36 | 29 | 31 |
Progression-free survival | 77 | 50 | 40 | 43 |
Metastatic progression-free survival | 82 | 57 | 45 | 43 |
Prostate cancer-specific survival | 88 | 67 | 61 | 52 |
Overall survival | 83 | 64 | 48 | 48 |